Navigation Links
Signalife Sees Accretive Purchase and Financial Commitments
Date:3/17/2008

LOS ANGELES, March 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) announced earlier today that it has received several formal purchase and financial commitments with respect to acquisitions of the Company's technology licenses, devices and services. These commitments have come internationally, including in Japan, other parts of Asia and Europe, as well as domestically.

Dr. Harmison, the Company's President and CEO, stated: "I anticipate closing these transactions in the upcoming two to four weeks, which comprise significant business for the Company. With the experiential base developed during my tenure regarding the ECG data generated from the usage of our technologies -- not only by health care providers but also through numerous Athletes for Life-sponsored mobile health care screenings -- there are now numerous additional revenue streams that have naturally become available to the Company. Indeed, physicians have provided me with a variety of data and information following very successful screenings this past weekend on the Athletes for Life Mobile Health Center in Temecula, California. With this kind of data garnered from real patients in the field, the foundation for the expansion of our life-saving devices becomes stronger every day."

The Company did not state the exact amount of business contemplated by these developments, and it cautioned that there is no certainty that any of the transactions will close as contemplated -- or at all.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Wins Second Frost & Sullivan Technology Award
2. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
3. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
4. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
5. U.S. Patent 7,299,083 Awarded to Signalife
6. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
7. Signalife Continues to Procure Purchase Orders, Revenues
8. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
9. Signalife Receives Another $3.3 Million Sales Orders
10. Signalife Achieves $1.98 Million Sales Orders Thus Far
11. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):